Newswise — Boston, Ma., (July 9, 2019) – Joslin Diabetes Center, an affiliate of Harvard Medical School, announced that Todd Abbrecht, Head of Private Equity at Thomas H. Lee Partners, has been elected to its Board of Trustees.
“We are very pleased to welcome Todd to our Board of Trustees,” said Peter Amenta, M.D., Ph.D., President and CEO of Joslin Diabetes Center. “Todd has an extensive background in business and finance. His expertise will provide a critical perspective to our board. He will be of tremendous support to us in our mission to improve the lives of those living with diabetes through innovative research and clinical care. We look forward to working with him.”
Todd Abbrecht is Head of Private Equity and a member of the management committee at Thomas H. Lee Partners (THL). Since 1992, Mr. Abbrecht has been involved in the execution of THL's investments in the consumer and healthcare space. Prior to joining THL, Mr. Abbrecht worked at Credit Suisse First Boston in its mergers and acquisitions department.
Mr. Abbrecht was elected to a three-year term at the June Board of Trustees meeting.
Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 16 NIH-designated Diabetes Research Centers in the U.S.